# Eubulus Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eubulus-biotherapeutics

- Industry: Pharmaceuticals
- Headquarters: Jiaxing, China
- Latest round: Series A (Oct 12, 2021)
- Investors on record: 3

## About

Based in Jiaxing, China, and founded in 2018, Eubulus Biotherapeutics Inc. is a pharmaceutical company engaged in targeted protein degradation technology. In October 2021, the company completed series A funding. The company's founder Dr, Xiaodong Cao graduated from Peking University, he has experience in protein structure-assisted small molecule drug design and molecular conjugates drug research and development. The core members of the R & D team have more than 20 years of drug development experience.

The company is committed to developing cell and tissue-targeted protein degradation drugs, that can be applied in tumor treatment. The company focuses on solving the problem of poor drug properties of molecules and provides a solution for the transformation of protein degradation technology in drugs.

The latest funding will accelerate the clinical process of bifunctional degradation agents and fill the demand for tumor treatment.

## Funding rounds

- Series A, Oct 12, 2021 — Changrong Capital, Star Capital, Shanghai Daidai Investment Consulting Ltd.

## Investors

- Changrong Capital — Series A
- Star Capital — Series A
- Shanghai Daidai Investment Consulting Ltd. — Series A